Allakos Receives $32,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=28514a7b-3e38-484f-a66f-3863db024821&Preview=1 - Date
12/18/2012 - Company Name
Allakos - Mailing Address
Undisclosed San Francisco, CA 94105 - Company Description
Allakos Inc. is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 (Th2) immune response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept. - Website
http://www.allakos.com - Transaction Type
Venture Equity - Transaction Amount
$32,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Novo A/S - Venture Investor
Alta Partners - Venture Investor
RiverVest Venture Partners - Venture Investor
Roche Venture Fund
